Primary Progressive Multiple Sclerosis (PPMS) - UK Overview

  • ID: 4449256
  • Report
  • Region: United Kingdom, Great Britain
  • 73 pages
  • Pharma Scroll
1 of 4

FEATURED COMPANIES

  • AB Sciences
  • Actelion
  • Bayer
  • Genzyme
  • Medicinova
  • Novartis
  • MORE
Primary Progressive Multiple Sclerosis (PPMS) as a disease area has a high market potential but not many drugs are approved and hence has a high unmet need.

The report gives the overview of Primary Progressive multiple sclerosis disease indication in detail in UK market, highlights the PPMS epidemiology in UK, elaborates on the drugs prescribed and expected to be prescribed in PPMS and covers the detailed market sizing drug wise in UK in value sales and patient numbers along with forecast. The report elaborates on the Primary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a PPMS patient, Symptoms of PPMS patient, and disease progression in a PPMS patient.

The report further highlights the multiple methods through which the patient can be diagnosed for PPMS. The next part of the report consists of PPMS epidemiology and prevalence in UK. The epidemiology for PPMS indication has been forecasted till 2024 as well in the report. The next part of the report highlights the importance of factors influencing the physician prescription decisions in PPMS like efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in PPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of drug in the PPMS market. The report further details the drug attribute analysis drug wise on each parameter considered important in the prescription of PPMS drugs. The report also covers the other products which are currently in the pipeline for PPMS and other progressive forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise in UK both in terms of value sales and patient numbers. The drugs have been forecasted till 2030 both for value sales and patient numbers in UK.

Products Covered:
  • Masitinib
  • Laquinimod
  • Lemtrada
  • Ocrelizumab
  • Qizenday
  • Ibudilast
  • Idebenone
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Sciences
  • Actelion
  • Bayer
  • Genzyme
  • Medicinova
  • Novartis
  • MORE
Multiple Sclerosis Definition
Types of MS
PPMS definition
Causes of PPMS
Profile of PPMS patient
Symptoms of PPMS patient
Disease progression and impact on QoL
Disease diagnosis
Disease Epidemiology in UK
Factors influencing Physician prescription decision
DMTs for PPMS
Drug Attribute analysis
Pipeline products in PPMS
PPMS Market sizing drug wise including value sales and patient numbers in UK
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biogen
  • Novartis
  • Sanofi
  • Sanofi Genzyme
  • Genzyme
  • Active Biotech
  • Merck
  • Teva
  • Bayer
  • Actelion
  • Medday Pharmaceuticals
  • Abbvie
  • Santhera Pharmaceuticals
  • AB Sciences
  • Roche
  • Medicinova
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll